Accordingly, GSPT1-selective immunomodulatory drugs [10], such as CC-90009, MRT-2359, and SJ6986 [20, 21, 36], have been developed, and CC-90009 and MRT-2359 are currently being explored in clinical trials involving patients with acute myeloid leukemia and lung cancer, respectively. This evidence concerns the gene GSPT1 and acute myeloid leukemia.